Understanding The Role of STON2 in Disease Development (G85439)

Target Name: STON2

NCBI ID: G85439

STON2

Understanding The Role of STON2 in Disease Development

STON2, short for Stoned B Homolog 2, is a gene that has been identified as a potential drug target for several diseases, including cancer, addiction, and neurodegenerative disorders. Its unique genetic mutation has led to the production of a unique protein that has been shown to contribute to the development and progression of these conditions.

The protein produced by the STON2 gene is known as STN2, which stands for Stoned B Homolog 2. It is a transmembrane protein that is expressed in many different tissues and cells in the body. Its function is not well understood at this time, but research has shown that it plays a role in various physiological processes, including cell signaling, DNA replication, and cell survival.

One of the most significant things about STN2 is its unique genetic mutation. It has been identified as a missense mutation, which means that a single nucleotide has been changed in a way that changes the way the protein is made. This mutation has led to the production of a protein that is very different from the typical version of STN2.

The missense mutation has led to the production of a protein that is unstable and prone to undergo conformational changes. These changes can have a number of different effects on the function of the protein and the body as a whole. For example, one of the changes that has been observed is that the protein is able to interact with and inhibit the activity of a protein called Bcl-2.

Bcl-2 is a protein that has been shown to contribute to the development and progression of a number of diseases, including cancer. It is also a potential drug target for several drugs, including some that are currently in use to treat cancer. By inhibiting the activity of Bcl-2, the missense mutation has been shown to have negative effects on the growth and survival of cancer cells.

Another potential effect of the missense mutation is its ability to contribute to the development of neurodegenerative disorders. Neurodegenerative disorders are a group of conditions that are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles. These conditions include Alzheimer's disease, Parkinson's disease, and Huntington's disease.

The missense mutation has also been shown to contribute to the development and progression of addiction. Addiction is a complex and multifaceted condition that is characterized by the compulsive need to seek out and consume drugs or other substances. The missense mutation has been shown to contribute to the development of addiction by changing the way that the brain processes dopamine, a chemical that is involved in pleasure and motivation.

In conclusion, STON2 is a gene that has been identified as a potential drug target for several diseases. Its unique genetic mutation has led to the production of a protein that is different from the typical version of STN2, and these differences have been shown to have negative effects on a number of physiological processes in the body. Further research is needed to fully understand the role of STON2 in these conditions and to develop effective treatments.

Protein Name: Stonin 2

Functions: Adapter protein involved in endocytic machinery. Involved in the synaptic vesicle recycling. May facilitate clathrin-coated vesicle uncoating

The "STON2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STON2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets